Indian J Pharm Close
 

Table 12: Question 4 (ii): What is the most appropriate choice of therapy for HR +ve/ Her2 −ve breast cancer post‑menopausal patients who have progressed on previous therapy with an AI and have no visceral crisis?

Table 12: Question 4 (ii): What is the most appropriate choice of therapy for HR +ve/ Her2 −ve breast cancer post‑menopausal patients who have progressed on previous therapy with an AI and have no visceral crisis?